Your 2023 wildcard predictions revealed
Will biotech lead a bull market recovery? Will Novartis spin off its cell therapy business? Read on for some of your leftfield predictions for biopharma.
Ash 2022 – the sickle cell race hots up
Sangamo emulates Editas, while Crispr/Vertex and Bluebird add weight to their ambitions.
Ash 2022 – Adicet has a case of déjà vu
Investors got jittery on Friday, and for good reason: like all allogeneic cell therapy players Adicet is seeing patients relapse.
Ionis gets into gene editing
The company insists its $80m tie-up with Metagenomi will not lead to a loss of focus.
Ash 2022 preview – waiting for Editas
Data on the group’s sickle cell project do not feature in the regular abstracts, while Bluebird walks away from its short hairpin contender.
The gloom deepens for biopharma stocks
With most glimmers of hope extinguished in the third quarter, 2022 is shaping up to be an annus horribilis for sector share prices.
